Lactobacillus reuteri لـ Bloating and Intestinal Gas
B الأدلة تدعم ذلك تجربة عشوائية واحدة على الأقل، مع نتائج متسقة في معظمها.Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.
الخلاصة
Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.
Key Study Findings
المجتمع المدروس: Adults with NAFLD diagnosed via FibroScan
المجتمع المدروس: Adults with functional constipation
المجتمع المدروس: Adults with functional bloating
المجتمع المدروس: Children with H. pylori infection
المجتمع المدروس: Children aged 6-15 with functional abdominal pain
Key Statistics
7
الدراسات
500
المشاركون
Positive
التقييم
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
الجرعات الشائعة
- general:
- 100 million - 5 billion CFU/day
- infantilecolic:
- 100 million CFU/day (DSM 17938 strain, 5 drops)
- adultgisupport:
- 1-5 billion CFU/day
الحد الأعلى: Well-tolerated up to 10 billion CFU/day in clinical trials
الجرعات المدروسة في الأبحاث
| الجرعة | المدة | التأثير | ن |
|---|---|---|---|
| Lactobacillus reuteri E9 (dose not specified) | -- | Positive | -- |
| None | -- | Positive | 65 |
| 4x10^8 CFU (induction), 2x10^8 CFU (standard) | 15 weeks | Positive | 56 |
| None | -- | Positive | 54 |
| None | -- | Positive | 3122 |
| L. reuteri DSM 17938 (1e8 CFU twice daily) | 16 weeks | Positive | 101 |
| None | 4 weeks | Positive | -- |
أفضل وقت للتناول: Before meals or on empty stomach; for infants, add drops to breast milk or formula
Safety & Side Effects
الآثار الجانبية المُبلّغ عنها
- ⚠ Mild gas in initial days of use
- ⚠ Occasional increased fussiness in infants during adjustment (transient)
- ⚠ Rare loose stools
- ⚠ Very rare: bacteremia in immunocompromised individuals
التفاعلات المعروفة
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
الحد الأقصى المسموح به: Well-tolerated up to 10 billion CFU/day in clinical trials
استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.
Frequently Asked Questions
Does Lactobacillus reuteri help with Bloating and Intestinal Gas?
How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?
Are there side effects of Lactobacillus reuteri?
How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?
Related Evidence
مكونات أخرى لـ Bloating and Intestinal Gas
Lactobacillus reuteri لحالات أخرى
References
- [1] Yongcheng Jiang et al.. Front Biosci (Landmark Ed). 2025. Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA. doi:10.31083/FBL39587 PubMed
- [2] Shamim Naizr et al.. Euroasian J Hepatogastroenterol. 2025. Incidence and Characterization of SIBO in NAFLD Patients. doi:10.5005/jp-journals-10018-1468 PubMed
- [3] G Riezzo et al.. Benef Microbes. 2018. Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation. doi:10.3920/BM2017.0049 PubMed
- [4] Ovidiu Burta et al.. Transl Gastroenterol Hepatol. 2018. Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical … doi:10.21037/tgh.2018.09.11 PubMed
- [5] Jue-Rong Feng et al.. Eur J Clin Pharmacol. 2017. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. doi:10.1007/s00228-017-2291-6 PubMed
- [6] Zvi Weizman et al.. J Pediatr. 2016. Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. doi:10.1016/j.jpeds.2016.04.003 PubMed
- [7] Behnaz Amirimani et al.. Middle East J Dig Dis. 2013. Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial. PubMed
إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.